Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ Failure

• Main Authors: Fatih M. Uckun (Author), James Carlson (Author), Cemal Orhan (Author), Joy Powell (Author), Natalie M. Pizzimenti (Author), Hendrik van Wyk (Author), Ibrahim H. Ozercan (Author), Michael Volk (Author), Kazim Sahin (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: New treatment platforms that can prevent acute respiratory distress syndrome (ARDS) or reduce its mortality rate in high-risk coronavirus disease 2019 (COVID-19) patients, such as those with an underlying cancer, are urgently needed. Rejuveinix (RJX) is an intravenous formulation of anti...